Secondary leukemia following successful treatment of Wilms' tumor.
Leukemia accounts for 15-20% of the secondary malignancies among survivors of Wilms' tumor. We report three patients who developed leukemia after the successful treatment of Wilms' tumor, each of whom demonstrates the importance of close long-term medical surveillance. The first patient developed Philadelphia chromosome positive chronic myelogenous leukemia (CML) 6 years after the diagnosis of Wilms' tumor. This is the second report of CML occurring after Wilms' tumor. The other two patients developed acute nonlymphocytic leukemia (ANLL) 3 and 18 years after successful treatment of Wilms' tumor. In one patient, the clinical manifestations were subtle, and in the other the latency period was the longest reported for secondary leukemia following Wilms' tumor. We conclude that survivors of childhood cancer require frequent medical surveillance even in their adult years.
Moss
T J
TJ
Gwynne Hazen Cherry Memorial Laboratory, Jonsson Cancer Center, UCLA School of Medicine, Department of Pediatrics 90024.
Strauss
L C
LC
Das
L
L
Feig
S A
SA
D000477:Alkylating Agents / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology* / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D015470:Leukemia, Myeloid, Acute / Q000473:pathology*; D009378:Neoplasms, Multiple Primary / Q000473:pathology*; D009396:Wilms Tumor / Q000473:pathology* / Q000628:therapy
D000477:Alkylating Agents; D000970:Antineoplastic Agents